Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Krystal Biotech Inc
(NQ:
KRYS
)
184.55
-4.71 (-2.49%)
Streaming Delayed Price
Updated: 12:21 PM EDT, Sep 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Krystal Biotech Inc
< Previous
1
2
3
4
Next >
This Stock Has Quadrupled in 5 Years. Can It Do It Again?
November 10, 2023
Have investors already missed the boat with this stock?
Via
The Motley Fool
Earnings Scheduled For November 6, 2023
November 06, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Via
Benzinga
A Preview Of Krystal Biotech's Earnings
November 03, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
October 24, 2023
Via
Benzinga
5 Analysts Have This to Say About Krystal Biotech
October 12, 2023
Via
Benzinga
5 Analysts Have This to Say About Krystal Biotech
September 07, 2023
Via
Benzinga
Analyst Ratings for Krystal Biotech
August 08, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2023
October 12, 2023
Via
Benzinga
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
September 15, 2023
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.
Via
Investor's Business Daily
Exposures
Product Safety
Krystal Biotech Sells Rare Pediatric Disease Priority Review Voucher For $100M
August 21, 2023
Krystal Biotech, Inc. (NASDAQ: KRYS) has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV)
Via
Benzinga
Expert Ratings for Krystal Biotech
July 03, 2023
Via
Benzinga
What Will AbbVie Buy Next?
June 28, 2023
Two mid-cap drugmakers stand out as logical targets for AbbVie.
Via
The Motley Fool
Up 48% in 2023, Is This Biotech Stock a Buy?
June 03, 2023
How much longer can this biotech's run last?
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023
September 07, 2023
Via
Benzinga
3 Biotech Stocks to Buy Before the Breakout
July 28, 2023
Explosive growth and rapid innovation lie ahead for these three biotechnology stocks, making them the ones to watch.
Via
InvestorPlace
Why Shares of Krystal Biotech Are Rising Monday
May 22, 2023
The company is moving quickly to market its newly approved therapy.
Via
The Motley Fool
Analyst Expectations for Krystal Biotech's Future
May 22, 2023
Via
Benzinga
Expert Ratings for Krystal Biotech
February 28, 2023
Via
Benzinga
Krystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of Medicine
December 15, 2022
Via
Benzinga
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
August 07, 2023
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of...
Via
Benzinga
2 Soaring Stocks With More Upside Potential
July 21, 2023
Are these mid-cap stocks giants in the making?
Via
The Motley Fool
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter
June 06, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Unlocking a $750 Million Opportunity: Krystal Biotech's Vyjuvek and its Potent Impact on Dystrophic Epidermolysis Bullosa Treatment
May 22, 2023
The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for treating patients six months of age or older with
Via
Benzinga
FDA Approves First Redosable Gene Therapy, Krystal Biotech's Treatment For Skin Blistering Disorder
May 22, 2023
The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic
Via
Benzinga
NVIDIA To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday
May 22, 2023
Needham cut the price target for Wix.com Ltd. (NASDAQ: WIX) from $125 to $120. Needham analyst Bernie McTernan maintained a Buy rating. Wix.com shares dropped 3.2% to close at $78.09 on Friday.
Via
Benzinga
Dentsply Sirona, Chico's FAS, Kontoor Brands And Other Big Stocks Moving Higher On Tuesday
February 28, 2023
U.S. stocks traded lower, with the Dow Jones dropping more than 150 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
April 18, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
February 28, 2023
Via
Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
December 25, 2022
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.
Via
Benzinga
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
December 18, 2022
Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year.
Via
InvestorPlace
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.